Zileuton
Zileuton is a 5-lipoxygenase (5-LOX) inhibitor that blocks the enzyme responsible for converting arachidonic acid to 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and subsequently to leukotrienes, potent inflammatory mediators that cause bronchoconstriction, mucus secretion, and inflammatory cell recruitment in asthma. It is approved for the prophylaxis and chronic treatment of asthma, reducing leukotriene-mediated airway inflammation and bronchoconstriction. Its direct enzyme inhibition of leukotriene synthesis distinguishes it from leukotriene receptor antagonists like montelukast.
Peso molecular
236,2900 g/mol
LogP
1,60
TPSA
94,80 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CC(c1cc2ccccc2s1)N(O)C(N)=O
InChI
InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)
Molecular Formula
C11H12N2O2S
HBD / HBA
2 / 3
Enlaces Rotables
2
Átomos Pesados
16
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Zileuton is a 5-lipoxygenase (5-LOX) inhibitor that blocks the enzyme responsible for converting arachidonic acid to 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and subsequently to leukotrienes, potent inflammatory mediators that cause bronchoconstriction, mucus secretion, and inflammatory cell recruitment in asthma. It is approved for the prophylaxis and chronic treatment of asthma, reducing leukotriene-mediated airway inflammation and bronchoconstriction. Its direct enzyme inhibition of leukotriene synthesis distinguishes it from leukotriene receptor antagonists like montelukast.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Zileuton is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL93. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 60490. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="zileuton"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/zileuton/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/zileuton/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/zileuton/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="zileuton"></drugfyi-drug>